Sanofi and Regeneron have reported positive results from a Phase II clinical trial of dupilumab for the treatment of adults with active moderate to severe eosinophilic oesophagitis.

Dupilumab is a human monoclonal antibody being developed for simultaneous inhibition of overactive signalling of IL-4 and IL-13 cytokines that are reportedly involved in type 2 inflammation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Results indicated that subjects administered weekly with dupilumab experienced a significant improvement in the ability to swallow at week ten, when compared with placebo.

In a total of 47 patients, the randomised, 12-week Phase II trial evaluated 300mg dupilumab after a 600mg loading dose.

The trial’s primary endpoint was change in swallowing difficulty from baseline to week ten measured as Straumann Dysphagia Instrument (SDI) score.

Northwestern University Feinberg School of Medicine professor Ikuo Hirano said: “Currently, there are no US Food and Drug Administration (FDA) approved therapies for eosinophilic oesophagitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“These positive Phase II results support further clinical development of dupilumab for patients with eosinophilic oesophagitis.”

“These positive Phase II results support further clinical development of dupilumab for patients with eosinophilic oesophagitis.”

Dupilumab is reported to have achieved the Phase II trial secondary endpoints, including decreased mean change in the Eosinophilic Oesophagitis Endoscopic Reference Score (EoE-EREFS), overall peak intraepithelial eosinophil count, and composite measures of symptoms and quality of life.

The FDA has granted orphan drug designation to dupilumab for the treatment of eosinophilic oesophagitis.

Additionally, the drug candidate is being studied by the firms in separate Phase III trials for paediatric atopic dermatitis, uncontrolled persistent asthma and nasal polyps.